AstraZeneca PLC
11778.00
18-February-25 11:29:56
15 minutes delayed
Stocks
+54.00
+0.46%
Today's range
11683.00 - 11844.00
ISIN
N/A
Source
Cboe
-
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
25 Apr 2024 12:52:49 By NASDAQ US Markets
-
25 Apr 2024 11:30:48 By NASDAQ US Markets
-
25 Apr 2024 11:15:48 By NASDAQ Stocks
-
AstraZeneca Q1 Profit, Revenues Climb; Backs FY24 Outlook
25 Apr 2024 03:16:35 By NASDAQ US Markets
-
NetDania - New 12 months High: AstraZeneca PLC
25 Apr 2024 03:15:24 By NetDania Notify
-
ANGLE Reaches Deal With AstraZeneca To Advance DDR Assay For Circulating Tumor Cell Detection
24 Apr 2024 03:37:17 By NASDAQ US Markets
-
FDA Approves AstraZeneca And Daiichi Sankyo's Enhertu For Solid Tumors Treatment
05 Apr 2024 22:16:14 By NASDAQ US Markets
-
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
05 Apr 2024 09:38:12 By NASDAQ Stocks
-
AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod
02 Apr 2024 10:15:53 By NASDAQ Stocks
-
Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock
26 Mar 2024 18:07:03 By NASDAQ Stocks
-
AstraZeneca Announces FDA Approval For Ultomiris - Quick Facts
25 Mar 2024 03:55:20 By NASDAQ US Markets
-
Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca
20 Mar 2024 14:32:29 By NASDAQ Stocks
-
AstraZeneca To Buy Fusion Pharma For Up To $2.4 Bln
19 Mar 2024 03:31:51 By NASDAQ US Markets
-
AstraZeneca To Expand Savings Programs For US Inhaled Respiratory Portfolio
18 Mar 2024 07:40:23 By NASDAQ US Markets
-
First Week of AZN May 17th Options Trading
15 Mar 2024 12:39:15 By NASDAQ Stocks
-
AstraZeneca To Buy Amolyt Pharma For Up To $1.05 Bln To Expand Late-stage Rare Disease Pipeline
14 Mar 2024 03:46:14 By NASDAQ US Markets
-
AstraZeneca Announces Initiation Of Phase III Trial With BREZTRI
13 Mar 2024 07:41:44 By NASDAQ US Markets
-
AZN Crosses Above Key Moving Average Level
11 Mar 2024 16:51:21 By NASDAQ US Markets
-
AZN Crosses Above Key Moving Average Level
11 Mar 2024 16:44:19 By NASDAQ Stocks
-
AstraZeneca's Datopotamab Deruxtecan Applications Validated In EU For Lung Cancer, Breast Cancer
04 Mar 2024 03:26:38 By NASDAQ US Markets